Tumor Kinetics Prior to Treatment Correlate With Response to Checkpoint Inhibitors

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-3-s2-p252
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Pretreatment Nutritional Status and Response to Checkpoint Inhibitors in Lung Cancer

Lung Cancer Management
2020English

Review of Cancer Treatment With Immune Checkpoint Inhibitors

Wiener Klinische Wochenschrift
Medicine
2017English

Immune Response in Melanoma: A Basis to Understand the Role of Immunotherapy With Immune Checkpoint Inhibitors

Revista da Sociedade Portuguesa de Dermatologia e Venereologia
2018English

Resistance Mechanisms in Melanoma to Immuneoncologic Therapy With Checkpoint Inhibitors

2019English

Characterization of Tumor Mutation Burden, PD-L1 and DNA Repair Genes to Assess Relationship to Immune Checkpoint Inhibitors Response in Metastatic Renal Cell Carcinoma

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Treatment-Related Adverse Events and Response Rate to Immune Checkpoint Inhibition

Journal of International Medical Research
BiochemistryMedicineCell Biology
2019English

Biomarkers for Immune Checkpoint Inhibitors: The Importance of Tumor Topography and the Challenges to Cytopathology

Cancer cytopathology
Cancer ResearchOncology
2017English

2) Lung Cancer Treatment Using Immune Checkpoint Inhibitors

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
Medicine
2019English

Local Angiotensin II Contributes to Tumor Resistance to Checkpoint Immunotherapy

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy